Login
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc.

tarsusrx.com

What Do They Do?

Sells XDEMVY, an eye drop for Demodex blepharitis, to specialty pharmacies and distributors, and develops medicines for other eye diseases and infectious disease prevention.

How Do They Make Money?

Tarsus earns revenue by selling XDEMVY to U.S. specialty pharmacies and distributors; product sales count when the medicine is delivered. It has also earned fees for granting a partner rights to market TP-03 in China.

revenue
SegmentShareRevenue
Product sales, net
Sold outright

100%
FY2022: 0.0%
License fees and collaboration revenue
Licensed
0.0%
FY2022: 100%

Who Are Their Customers?

Tarsus sells XDEMVY to specialty pharmacies and distributors, which then sell it to clinics, hospitals, pharmacies and federal healthcare programs.

Do Revenues Turn Into Profits?

No. It lost $66.4M in FY2025.

Operating income, FY2025
−16% of revenue
▲ +41% (Loss) vs FY2024 (−$120.6M, −66%)
Net income, FY2025
−15% of revenue
▲ +43% (Loss) vs FY2024 (−$115.6M, −63%)
Free cash flow, FY2025
−5% of revenue
▲ +74% (Loss) vs FY2024 (−$84.6M, −46%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +64%
vs $118.7M in Q3 FY2025
Net income
▼ −5211% (Loss)
vs −$12.6M in Q3 FY2025
Product sales, net share of revenue vs 100.0% in Q3 FY2025
  • Sep 4, 2026 Completed acquisition of Alkeus Pharmaceuticals Alkeus became a wholly owned subsidiary, with additional payments tied to U.S. approval and first sale.
  • Jul 8, 2026 Acquired iRenix Medical The acquisition adds IRX-101, an investigational ocular antiseptic for intravitreal procedures.

Growing. Revenue grew 7.9x in 4 years, from $57M in FY2021 to $451.4M in FY2025, about 68% a year.

From development to sales The lead program moved from an investigational eye drop for Demodex blepharitis to a marketed treatment for the condition.

Revenue over time
Product sales, net License fees and collaboration revenue
$500M$250M$0

Who Do They Compete With?

Competes with Azura Ophthalmics, Aperta Biosciences, Formosa Pharmaceuticals, Glaukos, Atticus Medical, Hovione Scientia, Premark Pharma, Viatris, and Quorum Innovations

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support